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Abstract: An acquired deficiency of interleukin-2 (IL-2) and related disturbances in regulatory T cell
(Treg) homeostasis play an important role in the pathogenesis of systemic lupus erythematosus (SLE).
Low-dose IL-2 therapy was shown to restore Treg homeostasis in patients with active SLE and its
clinical efficacy is currently evaluated in clinical trials. Lupus nephritis (LN), a challenging organ
manifestation in SLE, is characterized by the infiltration of pathogenic CD4+ T cells into the inflamed
kidney. However, the role of the Treg-IL-2 axis in the pathogenesis of LN and the mode of action of
IL-2 therapy in the inflamed kidneys are still poorly understood. Using the (NZB × NZW) F1 mouse
model of SLE we studied whether intrarenal Treg are affected by a shortage of IL-2 in comparison with
lymphatic organs and whether and how intrarenal T cells and renal inflammation can be influenced
by IL-2 therapy. We found that intrarenal Treg show phenotypic signs that are reminiscent of IL-2
deprivation in parallel to a progressive hyperactivity of intrarenal conventional CD4+ T cells (Tcon).
Short-term IL-2 treatment of mice with active LN induced an expansion the intrarenal Treg population
whereas long-term IL-2 treatment reduced the activity and proliferation of intrarenal Tcon, which was
accompanied by a clinical and histological amelioration of LN. The association of these immune
pathologies with IL-2 deficiency and their reversibility by IL-2 therapy provides important rationales
for an IL-2-based immunotherapy of LN.
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1. Introduction
Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease characterized by
the breach of self-tolerance to nuclear autoantigens leading to inflammation and tissue destruction in
multiple organ systems [1]. Lupus nephritis (LN) is a major contributor to the morbidity and mortality
in SLE [2]. As early as 1984, Austin et al. linked renal inflammation with lymphocyte infiltration in LN
and developed a scoring system for the histological assessment of LN [3]. Predominantly CD4+ T
cells that belong to the Th1 lineage infiltrate the inflamed kidneys and are a predictor for the degree of
renal inflammation in patients with LN [4–7]. Infiltrating CD4+ T cells thus play a crucial role for the
initiation and perpetuation of inflammatory processes in LN. Studies that directly address the role of
infiltrating immune cells in human organs are limited. Alternatively, the (NZB × NZW) F1 mouse
model can be used as a suitable model to investigate the role of immune cells in the pathogenesis of
LN [8].
Regulatory CD4+ T cells (Treg) that express the transcription factor FoxP3 are crucial for the
control of autoimmunity by suppressing the activation and differentiation of self-reactive T cells and
other pathogenic immune cells [9–11]. Their growth and survival fundamentally depend on the
availability of the immunoregulatory cytokine interleukin-2 (IL-2) [12,13]. In the (NZB × NZW) F1
mouse model of lupus and in human SLE patients we found that an acquired deficiency of IL-2 caused
a homeostatic disbalance between proliferating Treg and conventional CD4+ T cells (Tcon), which was
accompanied by the loss of CD25 expression on Treg and an accelerated Tcon hyperactivity in lymphatic
organs and peripheral blood [14,15]. These disturbances in the Treg-IL-2 axis were associated with
increased disease activity, thereby highlighting the importance of IL-2 deficiency in SLE pathogenesis.
Accordingly exogenous supplementation of IL-2 temporarily restored CD25 expression in Treg and the
homeostatic balance between Treg and Tcon, and was capable to reduce disease activity in lupus-prone
mice and also in SLE patients with active disease [14–18].
The coincidence of homeostatic and phenotypic abnormalities of the Treg population due to
IL-2 deficiency with the development of LN proposes that an impairment of intrarenal Treg also
contributes to renal inflammation. On the other hand, the fact that adoptive Treg transfers can delay the
progression of LN [14,19] suggests that Treg may be directly involved in the regulation of pathogenic
cells that infiltrate the inflamed kidneys. However, it is still unknown whether local or systemic IL-2
deficiency affects tissue-resident intrarenal Treg in analogy to lymphatic organs. In addition, the effects
of IL-2 therapy on the composition and phenotype of intrarenal Treg and Tcon and the reversibility of
organ-related pathologies associated with IL-2 deficiency are not well explored.
2. Materials and Methods
2.1. Mice
Female (NZB×NZW) F1 mice were bred at the Animal Facility of the Charité—University Medicine
Berlin and kept under a special pathogen-free condition at the Deutsches Rheuma-Forschungszentrum
(DRFZ), Berlin, Germany. All mice were grouped by age and disease activity and treated with
recombinant mouse IL-2 (R&D Systems, Minneapolis, MN, USA) or sterile PBS according to institutional
and federal guidelines (Landesamt für Gesundheit und Soziales, LaGeSo, Berlin, Germany).
2.2. Monitoring of Disease Activity and Definition of Disease Stages
Proteinuria was determined with Multistix 10 Visual (Siemens Healthcare Diagnostics Inc.,
Tarrytown, NY, USA). The following scoring system was used: Score 0 = 0 to 15 mg/dL,
score 1 = 30 mg/dL, score 2 = 100 mg/dL, score 3 = 100–300 mg/dL, score 4 = 300 mg/dL and
score 6 = 2000 mg/dL. The onset disease stage was defined as having a proteinuria score ranging from
0 to 3 and the nephritic stage as having a proteinuria score of >3.
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2.3. Cell Preparation
For the analysis of peripheral blood derived cells, 50–200 µL of whole blood was taken from the
tail veins of each animal at defined time points and before organs were harvested. Blood clotting was
prevented by using heparin (Liquemin, Roche Pharma AG, Grenzach-Wyhlen, Germany) containing
vials. Erythrocytes were lysed using a standard lysis buffer. Animals were sacrificed and spleens,
lymph nodes (superficial inguinal and axillary) and one kidney were separately mashed through cell
strainers (mesh size: 70 µm; BD Bioscience, Heidelberg, Germany) to obtain single cell suspensions.
Suspensions were dissolved in PBS containing 0.2% BSA and 2 mM EDTA and were stained with
fluorescently labeled antibodies.
2.4. Flow Cytometry
Cells were stained with indicated antibodies in PBS containing 0.2% BSA. For extracellular staining
the following fluorescently labeled antibodies were used: Anti-CD4-PerCP (GK1.5, eBioscience, Thermo
Fisher Scientific, Waltham, MA, USA), anti-CD44-Pacific Blue (IM7, DRFZ), anti-CD69-FITC (H1.2F3,
eBioscience) and anti-CD25-APC (PC61.5, eBioscience). For intracellular staining cells were fixed with
fixation buffer and afterwards permeabilized with perm buffer (Foxp3/transcription factor staining
buffer set, eBioscience) and then stained with anti-FoxP3-PE (FJK16s, eBioscience), anti-Helios-APC
(22F6, Biolegend, San Diego, CA, USA) and anti-Ki67-Pe-Cy7 (B56, BD Bioscience) with the appropriate
buffers according to the manufacturer’s protocol. Cells were stored in PBS containing 0.2% BSA and
0.01% sodium azide at 4 ◦C in the dark until measurement. Flow cytometry was performed using
MACS Quant (Miltenyi Biotech, Bergisch Gladbach, Germany) and data were analyzed using FlowJo V
9.6.1 (BD Bioscience).
Gating strategy: 1. Lymphocyte gate in the FSC/SSC plot. 2. Gating either for CD4+FoxP3+ Treg
or CD4+FoxP3− Tcon in a CD4/FoxP3 dot plot. 3. Frequencies of CD25+, CD69+, CD44hi, Ki67+
and Helios+ cells among gated CD4+FoxP3+ or CD4+FoxP3− cells were determined either by using
different dot plot combinations or by using histograms.
2.5. Intracellular Cytokine Staining
1 × 106 total splenocytes were stimulated for 5 h with 20 ng/mL PMA and 1 µg/mL ionomycin
(Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) together with Brefeldin A (Sigma-Aldrich) at a
final concentration of 2 µg/mL. After stimulation, cells were stained with anti-CD4-Pe-Cy7 (GK 1.5,
Biolegend) and anti-CD3-APCeFluor780 (17A2, eBioscience) in PBS and were afterwards fixed with BD
Bioscience Cytokines Fixation Kit (according to manufacturer’s protocol). After fixation, cells were
resuspended in 1× Perm buffer (BD Bioscience) and stained intracellularly with anti-IFNγ-FITC
(XMG1.2, BD Bioscience), anti-IL-2-APC (JES6-5H4, Biolegend) and anti-CD44-Pacific Blue (IM7, DRFZ).
2.6. Histological Analyses
Kidneys were fixed for at least 24 h in 4% paraformaldehyde immediately after harvesting.
Afterwards, organs were dehydrated, embedded in paraffin and cut into 1–2 µm consecutive sections.
Histochemical staining using hematoxylin and eosin (HE) as well as periodic acid Schiff (PAS) were
performed. Sections were scored in a blinded manner by one independent pathologist using the renal
activity index by Austin [3]. In detail, the activity index (AI) is the sum of six differentially weighted
histomorphological scores, which are glomerular cell proliferation (×1), leukocyte exudation (×1),
karyorrhexis and/or fibrinoid necrosis (×2), cellular crescents (×2), hyaline deposits (×2) and interstitial
inflammation and tubulitis (×1). Each score was scaled from 0 to 3 (0 = no changes, 1 = mild changes,
2 = moderate changes and 3 = severe changes).
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2.7. IL-2 Treatments
Disease activity and age-matched mice were injected subcutaneously either with 25 ng (2500 units)
per gram bodyweight (between 500 ng and 1000 ng per injection) of recombinant mouse IL-2 (R&D
systems, 402 ML) or with PBS alone every 24 h within the first five days (five times in total, short-term
treatment). In the long-term treatments, IL-2 injections were continued every four days as maintenance
treatment until day 29 (six additional injections). Mice were sacrificed and cells from different organs
and peripheral blood were analyzed 12 h (short-term treatment) or 48 h (long-term treatment) after the
last IL-2 injection.
2.8. Statistical Analyses
Graph Pad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA) was used for the
analysis. Statistical differences between two groups were analyzed by using the non-parametric Mann
Whitney U test. Correlation analyses were performed by using Spearman’s rank correlation coefficients.
Outliers were identified using the robust regression and outlier removal- (ROUT-) test. Cleared data
were used for further statistical analyses and graphs. Differences were considered significant if p values
were less than 0.05.
3. Results
3.1. Progressive Homeostatic Imbalance between Intrarenal Treg and Tcon
To obtain insights into the importance of Treg in the course of LN, we analyzed longitudinal
changes in the numbers, frequencies and phenotype of intrarenal CD4+FoxP3+ Treg and of intrarenal
CD4+FoxP3− Tcon during the progression of LN.
First, we correlated the quantities of intrarenal Treg and Tcon with the corresponding
histomorphological activity index (AI) and with the proteinuria index (PUI) in (NZB × NZW)
F1 lupus prone mice with different renal activity. Increases in absolute numbers of total intrarenal CD4+
T cells, of intrarenal CD4+FoxP3+ Treg and of intrarenal CD4+FoxP3− Tcon significantly correlated
with the AI and also with the PUI (Figure 1A,B). Calculation of the ratio between the absolute numbers
of Treg and of Tcon revealed a more pronounced increase in Treg numbers than in Tcon numbers
in correlation with the PUI (Figure 1C, left). Accordingly, the frequencies of intrarenal FoxP3+ Treg
among CD4+ T cells also correlated with the PUI (Figure 1C, middle). In general, the PUI significantly
correlated with the histomorphological AI (Figure 1C, right), suggesting that the PUI could be used as
an alternative measure for the degree of renal inflammation.
Next we determined the frequencies of proliferating cells among intrarenal Treg and Tcon by
using the proliferation marker Ki67. Here we could not observe significant correlations between the
PUI and the frequencies of Ki67+ cells neither among Treg nor among Tcon, although a moderate
decrease in Ki67+ Treg and a moderate increase in Ki67+ Tcon was apparent (Figure 1D). However,
the calculated ratio between proliferating intrarenal Ki67+ Treg and Ki67+ Tcon, representing a measure
of the homeostatic Treg/Tcon balance, continuously decreased in correlation with the PUI (Figure 1E).
This suggests that a progressive homeostatic imbalance between Treg and Tcon also develops in the
inflamed kidneys, comparable to findings in lymphatic organs and peripheral blood of these mice
(Figure S1A) [14] and to findings in patients with SLE [15].
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Figure 1. Progressive Treg/Tcon imbalance during progression of lupus nephritis. Cells from kidneys 
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numbers of total intrarenal CD4+ T cells, of intrarenal CD4+FoxP3+ Treg and of intrarenal 
CD4+FoxP3− Tcon in correlation with the renal histomorphological activity index (AI) (A) and with 
the proteinuria index (B). (C) Graphs show the correlation of the calculated ratio between absolute 
numbers of CD4+FoxP3+ Treg and CD4+FoxP3− Tcon (left graph), the correlation of the percentages 
of FoxP3+ cells among CD4+ T cells (middle graph) and the correlation of the AI with the proteinuria 
index (right graph). (D) The percentage of intrarenal Ki67+ cells among CD4+FoxP3+ Treg (left graph) 
and among CD4+FoxP3− Tcon (right graph) is shown. (E) The calculated ratio between percentages 
of Ki67+ Treg and of Ki67+ Tcon in correlation with the proteinuria index is shown. Data are derived 
from one kidney of each mouse from two to five independent experiments (n = 10 for correlations 
with AI; n = 28–30 for correlations with proteinuria index). Correlation analyses were performed by 
using Spearman’s rank correlation coefficients. Black lines indicate linear regression curves using 
Pearson analyses (*p < 0.05, **p < 0.01 and ***p < 0.001). 
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receptor α-chain, i.e., CD25, and increased expression of CD44 and CD69 as previously observed in the
lymphatic organs and peripheral blood of these mice [14]. Therefore we correlated the frequencies of
CD25, CD44 and CD69 expressing cells among Treg with the easy accessible PUI as an indicator of
nephritic activity. The frequency of CD25+ cells among intrarenal Treg remained unchanged during
progression of nephritis from the onset stage to the more active stages (Figure 2A). However, at the
onset stage the frequency of CD25+ cells among intrarenal Treg was significantly lower compared to
Treg from the spleens of the same disease stage and was in a similar range than in peripheral blood
(Figure S1B, left). Of note, Treg from spleens and peripheral blood of (NZB × NZW) F1 mice at the
onset stage of LN were shown to have already a reduced expression of CD25 when compared to Treg
from age-matched BALB/c mice or to young (NZB × NZW) F1 mice [14]. Similar to observations in
the spleens of (NZB × NZW) F1 mice, 50%–60% of the intrarenal Treg expressed the memory T cell
marker CD44 [20] (Figure S1B, middle), which however did not considerably change in the kidneys
during disease progression (Figure 2A, middle). CD69 has been considered to be a marker for recently
activated T cells [21], however more recently it has been shown that CD69 also plays an important
role in the retention of T cells in the inflamed organs [22]. The frequencies of CD69+ cells among
intrarenal Treg significantly correlated with the PUI (Figure 2A, right) and were significantly higher
than in the spleens at the disease onset (Figure S1B), suggesting a retention of intrarenal Treg at
the site of inflammation and a high activity of Treg already in the early phase of LN, which further
increases during the progression of LN. In conclusion, the phenotype of intrarenal Treg together with
the progressive homeostatic Treg/Tcon imbalance suggests that a deficiency of IL-2 is also present in the
inflamed kidneys of lupus-prone mice and such shortage of IL-2 occurs early during the course of LN.
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Figure 2. Phenotypic changes of intrarenal Treg and Tcon. Graphs show the percentage of CD25+,
CD44hi and CD69+ cells among CD4+FoxP3+ Treg (A) and among CD4+FoxP3– Tcon (B) in correlation
with the proteinuria index. Data are derived from one kidney of each mouse from two to five
independent experiments (n = 26). Correlation analyses were performed by using Spearman’s rank
correlation coefficients. Black lines indicate linear regression curves using Pearson analyses (* p < 0.05
and ** p < 0.01).
3.3. Increased Activation of Intrarenal Tcon
In parallel to the Treg analyses, we assessed phenotypic changes of intrarenal Tcon during the
progression of LN. The expression of CD25 is induced in Tcon upon activation independent of IL-2
availability and thus can be used as an activation marker for Tcon. The frequencies of CD25+ cells
among intrarenal Tcon considerably correlated with the PUI as an indicator of nephritic activity
(Figure 2B). The increases in the frequencies of CD25+ cells among Tcon between the onset stage and
the nephritic stage were in a similar range than in the spleens and peripheral blood of these mice
(Figure S1C). Corresponding to this, also the frequencies of CD44hi effector/memory cells among
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intrarenal Tcon markedly correlated with the PUI (Figure 2B). The frequencies of CD69+ cells among
intrarenal Tcon were at the same level than in spleens (Figure S1C), but did not change considerably
during progression of LN (Figure 2B). The increases in the frequencies of CD44hi cells among intrarenal
Tcon between the onset and nephritic stage were similar to those in the spleens and peripheral blood
(Figure S1C). These findings point to a progressive activation of intrarenal Tcon and an accumulation
of effector/memory Tcon in the inflamed kidneys.
3.4. Decrease of Intrarenal IL-2 Producing CD4+ Memory/Effector T Cells in Active LN
To assess whether shortage of IL-2 is present in the inflamed kidneys at a cellular level as suggested
by the data above, we determined the capability of intrarenal CD4+CD44hi memory/effector T cells
to produce cytokines in comparison to splenic memory/effector T cells of (NZB × NZW) F1 mice.
The frequency of IFN-γ producing cells among splenic CD4+CD44hi memory/effector T cells increased
during progression from the onset to the nephritic stage (Figure 3A). In parallel and in line with
previous findings in this lupus model [14], the frequency of IL-2 producing cells among splenic
CD4+CD44hi T cells declined (Figure 3B). In nephritic mice, frequencies of IL-2 and of IFN-γ producing
cells among intrarenal CD4+CD44hi T cells were in a similar range than in the spleens of nephritic mice
(Figure 3A, B), suggesting that a decrease of IL-2 producing Tcon and a concomitant predominance of
Th1 cells also occurs in the inflamed kidneys.
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3.5. Short-Term IL-2 Treatment Expands the Intrarenal Treg Population
The data above suggested that IL-2 deficiency, either locally or systemically, might contribute to
renal inflammation in (NZB × NZW) F1 mice. Therefore, (NZB × NZW) F1 mice with active nephritis
were treated daily with a subcutaneous injection of recombinant IL-2 (25 ng/g body weight) for 5
consecutive days. Intrarenal CD4+FoxP3+ Treg and CD4+FoxP3− Tcon were analyzed 12 h after the
last IL-2 injection and were compared to age- and disease activity-matched PBS-treated control mice.
Absolute numbers of total intrarenal CD4+ T cells, and more pronounced of CD4+FoxP3+
Treg and of CD4+FoxP3− Tcon increased approx. two-fold during the short-term IL-2 treatment
compared to control mice (Figure 4A–C). The frequencies of FoxP3+ Treg among intrarenal CD4+
T cells were significantly higher in IL-2 treated mice compared to controls (Figure 4D), indicating
that IL-2 preferentially expands the Treg population in the inflamed kidney. Although significant
increases in the frequencies of CD25+ cells among Treg were observed in peripheral blood and spleens
of IL-2 treated mice (Figure S3A), the frequency of CD25+ cells among intrarenal Treg was unaffected
(Figure 4E, left). Nonetheless, the geometric mean fluorescence intensity (gMFI) of CD25 in intrarenal
CD4+FoxP3+CD25+ Treg and of FoxP3 in intrarenal CD4+FoxP3+ Treg, representing the expression of
CD25 and FoxP3 on a per-cell basis, was significantly higher compared to the control group (Figure 4E
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right; Figure S2). In addition, the frequencies of Ki67+CD25+ among intrarenal Treg were higher in the
IL-2 treated mice compared to control mice (Figure 4F). This was also observed in peripheral blood but
not in spleens of the same mice (Figure S3C), which suggests that systemically administered IL-2 has
differing effects on Treg populations from different organs or compartments.
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Figure 4. Short-term IL-2 treatment expan trarenal Treg population. Cells from kidneys of
(NZB × NZW) F1 mice at the dis ase onset w re analyzed by flow cytometry 24 h after 5-d y treatment
course with daily injections of rIL-2 and compared with PBS-treated control mice. (A–C) Total numbers
of intrarenal CD4+ T cells (A), of intrarenal CD4+FoxP3+ Treg (B) and of intrarenal CD4+FoxP3- Tcon (C)
from IL-2 treated mice (IL-2) compared to control mice (CTRL) are shown. (D) Representative contour
plots and scatter plot show the frequencies of FoxP3+ cells among CD4+ T cells in IL-2 treated mice
compared to controls. (E) The frequency of CD25+ cells among CD4+FoxP3+ Treg and the geometric
mean fluorescence intensity (gMFI) of CD25 in CD4+FoxP3+CD25+ Treg are shown. (F) The percentage
of intrarenal CD25+Ki67+ cells among CD4+FoxP3+ Treg is shown. (G) The frequency of CD25+ cells
among CD4+FoxP3− Tcon and the gMFI of CD25 in CD4+FoxP3-CD25+ Tcon are shown. (H) The
calculated ratio between percentages of Ki67+ Treg and of Ki67+ Tcon is shown. Filled squares
indicate PBS treated control mice (CTRL, n = 9) and open squares represent IL-2 treated mice (IL-2,
n = 10). Horizontal lines represent the median. Mann-Whitney U test was used for statistical analyses
(* p < 0.05).
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Analysis of intrarenal Tcon revealed higher frequencies of CD25+ cells among Tcon in short-term
IL-2 treated mice compared to control mice (Figure 4G), which was not observed in spleens or peripheral
blood (Figure S3B). However, and in contrast to intrarenal Treg, the gMFI of CD25 in intrarenal CD25+
Tcon remained unaffected (Figure 4G) and neither changes in the frequencies of intrarenal Tcon
expressing Ki67, CD69 or CD44 (data not shown) nor changes in the Treg/Tcon proliferation ratio
(Figure 4H) were observed in short-term IL-2 treated mice. Of note, the proliferation ratio of Treg/Tcon
was significantly higher in the spleens of IL-2 treated mice, mainly due to a lower frequency of
proliferating cells among Tcon (Figure S3D). Taken together, intrarenal Treg of lupus prone mice could
be influenced by a short-term IL-2 treatment by means of numbers, phenotype and proliferation,
whereas with the exception of an increase in the frequency of CD25+ Tcon, intrarenal Tcon were
almost unaffected.
3.6. Long-Term IL-2 Treatment Diminishes the Activity of Intrarenal Tcon
In addition to the short-term experiments, we next assessed the effects of long-term IL-2 treatments
on intrarenal Treg and Tcon in comparison to spleens and peripheral blood from (NZB × NZW) F1
mice with active LN and whether there are differences in the AI determined by histomorphological
analyses of the kidneys. Mice were treated with IL-2 on 5 consecutive days (five injections in total)
followed by a maintenance treatment with repetitive IL-2 injections every four days for the duration of
29 days (six additional injections). Quantification of intrarenal CD4+ T cells at day 31 after the start of
the IL-2 treatments (48 h after the last IL-2 injection) revealed no significant differences in the absolute
numbers of total CD4+ T cells, of CD4+FoxP3+ Treg or of CD4+FoxP3- Tcon between IL-2 treated
and control mice (Figure 5A–C). Unexpectedly, the frequency of intrarenal Treg among CD4+ T cells
was significantly lower in the IL-2-treated mice compared to control mice (Figure 5D), which was not
observed in spleens or in peripheral blood of these mice (Figure S4A).
Phenotypical analyses of intrarenal Treg showed lower frequencies of CD69+ and Ki67+ cells
among Treg in IL-2 treated mice, whereas frequencies of CD44hi cells among Treg were unaffected by
the long-term IL-2 treatments (Figure 5E). Comparable changes in the frequencies of CD69+ and Ki67+
Treg could be observed in the spleens but not in the peripheral blood of IL-2 treated mice (Figure S4D).
Although frequencies of CD25+ cells among total intrarenal Treg did not increase in IL-2 treated mice
(data not shown), which was different to findings in the spleens (Figure S4D), we found significantly
higher frequencies of CD25+ cells among the Helios+FoxP3+ Treg subset, which is considered to be of
thymic origin [23], in the kidneys and also in spleens of IL-2 treated mice (Figure 5E, Figure S5).
In parallel to the effects on intrarenal Treg, we observed significantly lower frequencies of CD44hi
effector/memory cells among intrarenal Tcon in IL-2 treated mice compared to controls (Figure 5F).
In addition, frequencies of CD69+ cells and of proliferating, Ki67+ cells among intrarenal Tcon were
significantly lower in IL-2 treated mice compared to the control group (Figure 5F). Frequencies of
CD25+ cells among intrarenal Tcon did not change significantly under the IL-2 treatment (not shown).
Of note, frequencies and phenotype of intrarenal Treg and Tcon in long-term IL-2 treated mice with
active LN were in a comparable range as in (NZB × NZW) F1 mice at the onset stage (Figure 1).
Similar, but less pronounced, changes in the frequencies of CD25+, CD44hi, CD69+ and Ki67+ Tcon
were observed in spleens, but not in the peripheral blood of long-term IL-2 treated mice (Figure S4E).
Simultaneously performed histological analyses of the kidneys showed a significantly lower AI in IL-2
treated mice compared to control mice (Figure 6A–C). Complementary to this IL-2 treated mice also
had a lower PUI than control mice at day 31 (Figure 6D).
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nephritis at day 31 after the initiation of the IL-2 treatments (48 h after the last IL-2 injection; IL-2,
white bars) and compared to PBS-treated control mice (CTRL, black bars). (B) The six differentially
weighted histomorphological scores according to the AI are shown for the control and the IL-2 treated
group. (C) Representative images of hematoxylin and eosin stained kidney sections from either controls
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4. Discussion
An acquired deficiency of IL-2 profoundly affects Treg biology in lupus-prone individuals and
significantly contributes to the immune pathogenesis of SLE [14,24]. Low-dose IL-2 therapy currently
receives major attention in medicine as a novel and unique therapeutic approach, which is different
from conventional treatment strategies that commonly induce global immunosuppression [25,26].
Low-dose IL-2 therapy intends to restore Treg homeostasis and early phase clinical trials suggest that
this treatment is efficacious in large variety of autoimmune diseases including SLE [17,18,25,27,28].
Although it is undisputable that low-dose IL-2 therapy is capable to expand the Treg population very
efficiently and also quite selectively in virtually every treated patient, the mechanisms of action of
low-dose IL-2 therapy beyond Treg expansion are still not well understood [18,28,29]. In particular,
deeper insights into the IL-2 induced immunological changes in the inflamed tissues are necessary for
a better understanding of the modes of action of low-dose IL-2 therapy. In this study, we addressed
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whether kidney-infiltrating Treg are affected by a shortage of IL-2 and whether immune pathologies in
the inflamed kidneys can be influenced by exogenous administration of IL-2.
We found that already at the onset stage of LN, intrarenal Treg showed a reduced expression of
CD25, which was even lower than in Treg from spleens of these mice. The low expression of CD25 on
Treg represents a hallmark of IL-2 deficiency [13,14] and thus suggests an insufficient availability of
intrarenal IL-2 already at the early phase of LN. Complementary to these abnormalities we found low
frequencies of IL-2 producing cells among intrarenal effector/memory Tcon in mice with active nephritis.
The reduced availability of IL-2 in the inflamed kidneys of (NZB × NZW) F1 lupus-prone mice could
therefore result in impaired Treg growth and survival thereby impeding their capability to adequately
control the progressive hyperactivity of intrarenal effector/memory Tcon. Based on these findings,
it would be plausible to assume that numbers and frequencies of intrarenal Treg decline during the
progression of LN. Instead we observed an increase in both, the numbers and the frequencies of Treg
during the course of LN indicating a continuous enrichment or expansion of the Treg population in the
inflamed kidneys. Similar observations were made for Treg in the spleens of these mice and are also
reported for human SLE patients, where the frequencies of CD4+FoxP3+ Treg in the peripheral blood
correlated with disease activity [15,30]. In addition, already at the onset stage a large proportion of
intrarenal Treg expressed CD69 (a marker for tissue-resident cells and T cell activation) suggesting
that intrarenal Treg are in a highly active state and are retained in the inflamed kidney. Overall these
observations suggest a counter-regulatory mechanism attempting to dampen cellular hyperactivity in
LN that however may fail due to an insufficient availability of growth factors, such as IL-2 [14,24].
Another hallmark of IL-2 deficiency in SLE is the development of an imbalanced proliferation
between Treg and Tcon in favor of Tcon in lymphatic tissues and the peripheral blood [14,15]. Although
the proportions of proliferating cells among intrarenal Treg only moderately declined in parallel to
a moderate increase in the proportions of proliferating Tcon, the calculated Treg/Tcon proliferation
ratio, as a measure of the homeostatic balance between Treg and Tcon, significantly declined during
the progression of LN. This is analogous to findings in lymphatic organs of these mice [14] and
indicates that a progressive homeostatic Treg/Tcon imbalance develops also in the inflamed kidneys.
This also suggests that intrarenal Treg have a reduced capacity to efficiently control the expansion
of pro-inflammatory intrarenal Tcon. Thus, the progressive increase in frequencies and quantities
of intrarenal Treg that we observed during the course of LN might be the result of enhanced tissue
recruitment in order to compensate for the loss of control over Tcon activity in a numerical way [14,24].
Yet, the parallel increase in the numbers of kidney-infiltrating Tcon and their increased activation
proposes that during progression of LN Treg lose control over Tcon activation in the inflamed kidneys.
Based on these findings we hypothesized that systemic administration of IL-2 also directly affects
intrarenal Treg and thereby corrects the observed Treg defects in the kidneys. We found that short-term
IL-2 treatment for five consecutive days was capable to increase the numbers and frequencies of
intrarenal Treg. Simultaneously the expression levels of CD25 (gMFI) on Treg and the proportion of
proliferating CD25+ Treg were significantly augmented in the kidneys. This indicates that intrarenal
Treg can be targeted and modulated by IL-2 therapy, although the effects on intrarenal Treg appeared
to be in part different to those observed in spleens and peripheral blood. The reasons for these
organ-related differences in Treg responsiveness are unclear, but we suppose that this may be due to
differences in the distribution and clearance of IL-2 in the organism. It is known that kidneys are the
major site of clearance of circulating IL-2 in the body, which is mediated by both glomerular filtration
and peritubular extraction [31]. Thus, it could be speculated that intrarenal Treg are exposed to higher
levels of IL-2 than Treg in other organs. The transient increase in the frequencies of CD25+ cells among
intrarenal Tcon during the short-term IL-2 treatment is in line with recent findings in peripheral blood
of SLE patients treated with low doses of IL-2 and may indicate a certain lack of selectivity for Treg [18].
Yet, in consideration of the amelioration of LN and the reduction in activated intrarenal Tcon that was
observed during the long-term IL-2 treatment, such a transient activation of intrarenal Tcon may be
clinically rather negligible.
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Long-term IL-2 treatment led to a decreased activity and proliferation of intrarenal Tcon and in
parallel resulted in an amelioration of renal inflammation assessed by histomorphological scoring
of the kidney. The fact that the reduction of Tcon hyperactivity in the kidneys was only observed in
long-term treated mice and not in the short-term setting, suggests that multistep immunoregulatory
processes, most likely mediated by Treg, took place in the kidneys, and that direct and rapid effects of
IL-2 on the Tcon population, such as the induction of activated-induced cell death [32,33], were not
predominant in this setting.
Unexpectedly, and in contrast to findings in peripheral blood and spleens and also different
to the short-term treatment, the frequencies and numbers of intrarenal Treg and their proliferation
and activation state was lower in long-term IL-2 treated mice compared to controls. At first view,
such findings under long-term IL-2 treatment seem to be contradictory. However, we suppose that
the reduced quantities and activation state of intrarenal Treg under long term IL-2 treatment are
the consequence of the reduced activity of intrarenal Tcon, leading also to a lesser requirement of
counteracting Treg in the kidneys. Of note, both, frequencies and absolute numbers of intrarenal Treg
in long-term IL-2-treated mice were in the same range as in mice at the onset stage with less active LN.
Overall these findings further support that long-term IL-2 treatment is capable to decelerate or reverse
Tcon activity in the affected organs. Although no increase in the frequencies of CD25+ among total Treg
was observable in the kidneys of long-term IL-2 treated mice we found a significantly higher frequency
of CD25+ cells among the Helios+ Treg subset, suggesting a preferential targeting of thymic-derived
Treg by IL-2 therapy.
The results of our study are complementary to recent findings in the MRL/lpr mouse model of
SLE where it was shown that systemic administration of low doses of IL-2 decreases the numbers of
IL-17- producing, so called, double negative T cells in the spleens and in parallel reduces inflammation
in the kidneys and other affected organs [34]. More recently it was also shown in the (NZB × NZW) F1
model that treatment with IL-2/anti-IL-2 complexes induced an expansion of the Treg population in the
kidneys, which was accompanied by a reduction of kidney-infiltrating IFN-γ+CD4+ and IL-17A+CD4+
T cells and an amelioration of LN at a histomorphological and clinical level [35]. These data together
with our findings reasonably support the implementation of an IL-2-based immunotherapy in the
treatment of LN.
Limitations of our study include that we were not able to assess the suppressive function of
intrarenal Treg because of limited amounts of cells that can be isolated and sorted from the kidneys.
In addition, more detailed analyses of the effects of IL-2 on intrarenal T cell subsets, including Th1,
Th17, T follicular helper cells and CD8+ T cells or B cell subsets and NK cells are required for a deeper
understanding of the complex immunological processes that occur in the inflamed tissues under IL-2
therapy. Moreover, the diversity of potential suppressive mechanisms of Treg that take place in the
inflamed kidney including Treg-mediated cytotoxic effects on Tcon and other harmful immune cells is
well worth to be addressed in future studies.
In summary, our study proposed that a disturbance of the Treg-IL-2 axis contributed to the
pathophysiology of LN and particularly promoted the hyperactivity of intrarenal Tcon. The reversibility
of these immune pathologies in affected organs by IL-2 therapy shown here provided valuable insights
into the mechanisms of action of IL-2 therapy at a cellular level and offered additional rationales for an
IL-2-based immunotherapy of LN.
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